The dengue vaccine market is on track for robust growth, with increasing global awareness, governmental support, and ...

PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications • NAYA aiming to initiate clinical trials in earl ...

Compass Therapeutics Inc. has announced a new drug candidate, CTX-10726, a novel tetravalent PD-1 x VEGF-A bispecific antibody.

Half of the world's population is living in areas where dengue fever is present. Asian countries are most affected, reporting ...